Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study.
about
Feasibility of intraventricular administration of etoposide in patients with metastatic brain tumoursClinical Translation of Nanomedicine.Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.New agents for intrathecal administration.Clinical pharmacology of encapsulated sustained-release cytarabine.Lipid-based slow-release formulation of amikacin sulfate reduces foreign body-associated infections in mice.Liposomal cytarabine (DepoCyte) for the treatment of neoplastic meningitis.Leptomeningeal metastases from solid malignancy: a review.Pharmacology of drugs formulated with DepoFoam: a sustained release drug delivery system for parenteral administration using multivesicular liposome technology.A review of leptomeningeal metastases in pediatrics.Carcinomatous meningitis: Leptomeningeal metastases in solid tumorsMedulloblastoma in childhood: revisiting intrathecal therapy in infants and children.Diagnosis and individualized therapy of neoplastic meningitis.Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.Design and development of multivesicular liposomal depot delivery system for controlled systemic delivery of acyclovir sodium.Sustained release of hydroxycamptothecin after subcutaneous administration using a novel phospholipid complex-DepoFoam technology.A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.Extended-release formulation of morphine for subcutaneous administration.
P2860
Q28366035-17AA444E-3880-4961-99DA-4B5408DF5A94Q30355939-8883C62A-08F0-48A8-B95B-D2C7437122DFQ30366990-8C4BC414-3DCF-4533-B188-80B3A4808E73Q33999083-A577736C-DCFA-4C3A-93BF-31C4459558AAQ34072145-374B4A8B-BF4F-40B1-A408-98704720800BQ35117209-02DAE959-CF67-4AED-9B72-3B39027B35CDQ36244643-38CB4227-997A-4A86-B44D-B609AA6352BCQ36282162-8BFEB8B8-0F70-4E15-81FC-C75CD1B571DBQ36656404-F7165E2B-68F0-4A41-8783-765E9893FE4BQ36690632-8C366C91-0774-4526-88FC-3C5BB213E898Q36851197-023D8F25-87E4-40D1-8224-097CDB04DF8FQ37621288-C8613878-F321-4E59-8639-5ABFD10CBFD8Q37774360-24673CDD-5110-4A19-B86D-5684182D58EBQ38242272-5E4244E8-C2A9-4D11-A8FD-E9E65E6C9BC5Q41990308-53F873C5-41AD-47F5-94AA-96FBF7A8704DQ43048911-2C9E7EE5-D4C9-4340-99C6-04838CE5B77CQ43651159-33CD1E8D-5FE8-4EFE-92F4-1C1CD35C5836Q45984532-FFF4BAF3-A279-456E-885A-C863B727137BQ46055405-4C2EE4BB-D16C-461F-939C-280A6F3800BC
P2860
Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年学术文章
@wuu
1993年学术文章
@zh-cn
1993年学术文章
@zh-hans
1993年学术文章
@zh-my
1993年学术文章
@zh-sg
1993年學術文章
@yue
1993年學術文章
@zh
1993年學術文章
@zh-hant
name
Treatment of leptomeningeal me ...... ne (DTC 101). A phase I study.
@en
Treatment of leptomeningeal me ...... nistration of depot cytarabine
@nl
type
label
Treatment of leptomeningeal me ...... ne (DTC 101). A phase I study.
@en
Treatment of leptomeningeal me ...... nistration of depot cytarabine
@nl
prefLabel
Treatment of leptomeningeal me ...... ne (DTC 101). A phase I study.
@en
Treatment of leptomeningeal me ...... nistration of depot cytarabine
@nl
P2093
P1433
P1476
Treatment of leptomeningeal me ...... ine (DTC 101). A phase I study
@en
P2093
P304
P356
10.1001/ARCHNEUR.1993.00540030027009
P50
P577
1993-03-01T00:00:00Z